Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC-P intramuscular study in ALL/LBL after hypersensitivity to E. coli-derived asparaginases
2025-000263-36Phase 2
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Asparaginase erwinia chrysanthemi in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Response rate by last 72-hour NSAA during first course.
02
Drugs
Asparaginase erwinia chrysanthemi
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on 2025-000263-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000263-36.